This inventor holds 2 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 2 EPO patents. Top assignee: Nxera Pharma UK Limited. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Gregory R. Ott: Innovator in CGRP Antagonist Compounds
Introduction
Gregory R. Ott is a notable inventor based in North Wales, PA, specializing in the development of CGRP antagonist compounds. With a total of two patents to his name, he has made significant contributions to the field of pharmaceutical innovations.
Latest Patents
Ott's latest patents focus on novel compounds that target CGRP receptors. The first patent discloses compounds of Formula (1) and their salts, which are utilized in treating, preventing, ameliorating, controlling, or reducing the risk of disorders associated with CGRP receptors. The second patent presents compounds of Formula (1a) and their salts, also aimed at addressing disorders linked to CGRP receptors.
Career Highlights
Gregory R. Ott is currently associated with Nxera Pharma UK Limited, where he continues to advance his research and development efforts. His work is pivotal in the ongoing exploration of CGRP antagonists, which hold promise for various therapeutic applications.
Collaborations
Ott collaborates with esteemed colleagues, including Giles Albert Brown and Miles Stuart Congreve, contributing to a dynamic research environment that fosters innovation.
Conclusion
Gregory R. Ott's contributions to the field of CGRP antagonist compounds highlight his role as a significant inventor in the pharmaceutical industry. His work continues to pave the way for advancements in treatment options for disorders associated with CGRP receptors.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile